Outi Lahdenperä
- Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial (2022)
- Journal of Clinical Oncology
- Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema (2022)
- Journal of Plastic, Reconstructive and Aesthetic Surgery
- High baseline Tie1 level predicts poor survival in metastatic breast cancer (2019)
- BMC Cancer
- Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer (2019)
- Clinical Breast Cancer
- Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer The Randomized Clinical FinXX Trial (2017)
- JAMA Oncology
- Bevacizumab combined with docetaxel or paclitaxel as first-line treatment of HER2-negative metastatic breast cancer (2016)
- Anticancer Research
- Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX) (2014)
- Acta Oncologica
- Oral bioavailability of ospemifene improves with food intake (2013)
- International Journal of Clinical Pharmacology and Therapeutics